The worldwide Prenatal Diagnostic market has recently been published by Absolute Markets Insights. The statistical report offers an appropriate analysis of recent trends and technological advancements in global regions such as North America, Latin America, Asia-Pacific, Africa, and India. The data also uses useful tools, methodologies and standard operating procedures carried out by top-level industries to support its analysis. Moreover, the study also applies effective exploratory techniques such as primary and secondary research techniques. Some of the distinctive market key components of the global Prenatal Diagnostic market have been studied in order to get an extensive idea about the requirements of the businesses. Financial and economic aspects of the businesses have also been presented by means of graphical presentation techniques such as charts, graphs, tables, and pictures. The entire demand and supply chain has been explained with the help of penetrative insights into the businesses.
Top Players of Global Prenatal Diagnostic Market are Studied: Laboratory Corporation of America Holdings, Eurofins NTD, LLC, Abbott Laboratories, Hologic Inc., Illumina, Inc., Natera, Inc., PerkinElmer, Inc., Sequenom, Inc., Ariosa Diagnostics, Inc., and Ravgen. Inc. amongst others.
Click to view the full report: https://www.absolutemarketsinsights.com/reports/United-States-Prenatal-Diagnostic-Market-2018-2026-17
Prenatal diagnostics is used for testing the fetus before birth to determine certain hereditary disorders, for instance, Down's syndrome, hereditary sicknesses, chromosome abnormalities, neural tube defects, and other conditions. If high-risk is identified with the birth of a child, it can be assisted by conducting hereditary testing, common testing, and screening. The United States prenatal diagnostic market was valued at USD 527.5 Mn in 2020 and is expected to reach US$ 1,429.5+ Mn by 2030.
On the basis of test type, MaterniT21 PLUS Segment represented a major share in the U.S. Prenatal Diagnostic Market in 2016. The MaterniT21 PLUS test is indicated for use in pregnant women with increased risk for chromosomal aneuploidy. It analyzes circulating cell-free DNA extracted from a maternal blood sample. Rise in maternal age, and growing incidence of genetic abnormalities in newborns are the most significant drivers of these tests. Moreover, increased market penetration and competitive marketing methodologies by companies are further boosting the growth of these tests.
Prenatal Diagnostic Market:
By Type
- Prenatest, Verify
- Visibility
- Harmony
- InformaSeq
- MaterniT21 PLUS
- NIFTY
- Panorama
- Others)
By End-Use
- Hospitals
- Clinics
- Others
By Region
- North America
- Europe
- Asia Pacific
- Middle East and Africa
- Latin America
Contact Us:
Company: Absolute Markets Insights
Email id: sales@absolutemarketsinsights.com
Phone: +91-740-024-2424
Contact Name: Shreyas Tanna
No comments:
Post a Comment